Comparative Evaluation of Effect of Preoperative Oral Medication of Ibuprofen and Ketorolac on Anesthetic Efficacy of Inferior Alveolar Nerve Block with Lidocaine in Patients with Irreversible Pulpitis: A Prospective, Double-blind, Randomized Clinical Trial

Journal of Endodontics

Volumn 36, Issue 3, 2010, Pages 375-378

  Aggarwal, Vivek ^a   Singla, Mamta ^b   Kabi, Debipada ^a  

^a SAFDARJUNG HOSPITAL   (India)

^b INSTITUTE OF DENTAL STUDIES AND TECHNOLOGIES   (India)

Author keywords

Ibuprofen; inferior alveolar nerve block; irreversible pulpitis; ketorolac; NSAIDs

Indexed keywords

IBUPROFEN; KETOROLAC; LIDOCAINE; LOCAL ANESTHETIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ARTICLE; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENTAL ANESTHESIA; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; DRUG EFFECT; ENDODONTICS; FEMALE; HUMAN; MALE; MANDIBULAR NERVE; METHODOLOGY; NERVE BLOCK; NONPARAMETRIC TEST; PREMEDICATION; PROSPECTIVE STUDY; PULPITIS; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANESTHESIA, DENTAL; ANESTHETICS, LOCAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHI-SQUARE DISTRIBUTION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IBUPROFEN; KETOROLAC; LIDOCAINE; MALE; MANDIBULAR NERVE; NERVE BLOCK; PREANESTHETIC MEDICATION; PREMEDICATION; PROSPECTIVE STUDIES; PULPITIS; ROOT CANAL THERAPY; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 76449083120     PISSN: 00992399     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joen.2009.11.010     Document Type: Article

References (41)

1. Milgrom P. Four dimensions of fear of dental injections. J Am Dent Assoc 128 (1997) 756-762
2. Tortamano I.P., Siviero M., Costa C.G., Buscariolo I.A., and Armonia P.L. A comparison of the anesthetic efficacy of articaine and lidocaine in patients with irreversible pulpitis. J Endod 35 (2009) 165-168
3. Claffey E., Reader A., Nusstein J., Beck M., and Weaver J. Anesthetic efficacy of articaine for inferior alveolar nerve blocks in patients with irreversible pulpitis. J Endod 30 (2004) 568-571
4. Kennedy M., Reader A., Beck M., and Weaver J. Anesthetic efficacy of ropivacaine in maxillary anterior infiltration. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 91 (2001) 406-412
5. Goldberg S., Reader A., Drum M., Nusstein J., and Beck M. Comparison of the anesthetic efficacy of the conventional inferior alveolar, Gow-Gates, and Vazirani-Akinosi techniques. J Endod 34 (2008) 1306-1311
6. Cohen H.P., Cha B.Y., and Spangberg L.S. Endodontic anesthesia in mandibular molars: a clinical study. J Endod 19 (1993) 370-373
7. Childers M., Reader A., Nist R., Beck M., and Meyers W.J. Anesthetic efficacy of the periodontal ligament injection after an inferior alveolar nerve block. J Endod 22 (1996) 317-320
8. Dagher B.F., Yared G.M., and Machtou P. The anesthetic efficacy of volumes of lidocaine in inferior alveolar nerve blocks. J Endod 23 (1997) 178-180
9. Vreeland D.L., Reader A., Beck M., Meyers W., and Weaver J. An evaluation of volumes and concentrations of lidocaine in human inferior alveolar nerve block. J Endod 15 (1989) 6-12
10. Aggarwal V., Jain A., and Debipada K. Anesthetic efficacy of supplemental buccal and lingual infiltrations of articaine and lidocaine following an inferior alveolar nerve block in patients with irreversible pulpitis. J Endod 35 (2009) 925-929
11. Potočnik I., and Bajrović F. Failure of inferior alveolar nerve block in endodontics. Endod Dent Traumatol 15 (1999) 247-251
12. Rood J.P. Some anatomical and physiological causes of failure to achieve mandibular analgesia. Br J Oral Surg 15 (1977) 75-82
13. Parente S.A., Anderson R.W., Herman W.W., Kimbrough W.F., and Weller R.N. Anesthetic efficacy of the supplemental intraosseous injection for teeth with irreversible pulpitis. J Endod 24 (1998) 826-828
14. Hargreaves K.M., and Keiser K. Local anesthetic failure in endodontics: mechanisms and management. Endod Topics 1 (2002) 26-39
15. Chaudhary P., Martenson M.E., and Baumann T.K. Vanilloid receptor expression and capsaicin excitation of rat dental primary afferent neurons. J Dent Res 80 (2001) 1518-1523
16. Stenholm E., Bongenhielm U., Ahlquist M., and Fried K. VRl- and VRL-l-like immunoreactivity in normal and injured trigeminal dental primary sensory neurons of the rat. Acta Odontol Scand 60 (2002) 72-79
17. Goodis H.E., Poon A., and Hargreaves K.M. Tissue pH and temperature regulate pulpal nociceptors. J Dent Res 85 (2006) 1046-1049
18. Renton T., Yiangou Y., Baecker P.A., Ford A.P., and Anand P. Capsaicin receptor VR1 and ATP purinoceptor P2X3 in painful and nonpainful human tooth pulp. J Orofac Pain 17 (2003) 245-250
19. Ferriera S.H., and Vane J.R. New aspects of the mode of action of non-steroidal anti-inflammatory drugs. Annu Rev Pharmacol 14 (1974) 57-72
20. Dray A. Inflammatory mediators of pain. Br J Anaesth 75 (1995) 125-131
21. Lipsky P.E. Role of cyclooxygenase-1 and -2 in health and disease. Am J Orthop 28 suppl 3 (1999) 8-12
22. Willoughby D.A., Moore A.R., and Colville-Nash P.R. COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease. Lancet 355 (2000) 646-648
23. Uzan A. The unexpected side effects of new nonsteroidal anti-inflammatory drugs. Expert Opin Emerg Drugs 10 (2005) 687-688
24. FitzGerald G.A. Coxibs and cardiovascular disease. N Engl J Med 351 (2004) 1709-1711
25. Bresalier R.S., Sandler R.S., Quan H., et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352 (2005) 1092-1102
26. Solomon S.D., McMurray J.J., Pfeffer M.A., et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352 (2005) 1071-1080
27. US Food and Drug Administration. FDA issues public health advisory on Vioxx as its manufacturer voluntarily withdraws the product. FDA News September 30, 2004. Last update: 2007.
28. Varrassi G., Marinangeli F., Agro F., et al. A double-blinded evaluation of propacetamol versus ketorolac in combination with patient-controlled analgesia morphine: analgesic efficacy and tolerability after gynecologic surgery. Anesth Analg 88 (1999) 611-616
29. McQuay H.J., Poppleton P., Carroll D., et al. Ketorolac and acetaminophen for orthopedic postoperative pain. Clin Pharmacol Ther 39 (1986) 89-93
30. Fletcher D., Negre I., Barbin C., et al. Postoperative analgesia with IV propacetamol and ketoprofen combination after disc surgery. Can J Anaesth 44 (1997) 479-485
31. Mroszczak E., Jung D., Yee J., et al. Ketorolac tromethamine pharmacokinetics and metabolism after intravenous, intramuscular, and oral administration in humans and animals. Pharmacotherapy 10 (1990) 33-49
32. Modaresi J., Dianat O., and Mozayeni M.A. The efficacy comparison of ibuprofen, acetaminophen-codeine, and placebo premedication therapy on the depth of anesthesia during treatment of inflamed teeth. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 102 (2006) 399-403
33. Heft M.W., and Parker S.R. An experimental basis for revising the graphic rating scale for pain. Pain 19 (1984) 153-161
34. Abramovitz M., and Metters K.M. Prostanoid receptors. Ann Rep Med Chem 33 (1998) 223-231
35. Smith W.L., DeWitt D.L., and Garavito R.M. Cyclooxygenases: structural, cellular, and molecular biology. Ann Rev Biochem 69 (2000) 145-182
36. Miyamoto T., Ogino M., Yamamoto S., and Hayaishin O. Purification of prostaglandin endoperoxide synthetase from bovine vesicular gland microsomes. J Biol Chem 259 (1976) 2629-2636
37. Pilbeam C.C., Fall P.M., Alander C.B., and Raisz L.G. Differential effects of nonsteroidal antiinflammatory drugs on constitutive and inducible prostglandin G/H synthase in cultured bone cells. J Bone Miner Res 12 (1997) 1198-1203
38. Bhattacharya D.K., Lecomte M., Rieke C.J., Garavito R.M., and Smith W.L. Involvement of arginine 120, glutamate 524 and tyrosine 355 in the binding of arachidonate and 2- phenylpropionic acid inhibitors to the cyclooxygenase active site of ovine prostglandin endoperoxide H synthase-1. J Biol Chem 271 (1996) 2179-2184
39. Mancini J.A., Riendeau D., Falgueyret J.P., Vickers P.J., and O'Neill G.P. Arginine 120 of prostaglandin G/H synthase-1 is required for the inhibition by nonsteroidal anti-inflammatory drugs containing a carboxylic acid moiety. J Biol Chem 270 (1995) 29372-29377
40. Kurumbail R., Stevens A., Gierse J., et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 384 (1996) 644-648
41. Riendeau D., Charleson S., Cromlish W., Mancini J.A., Wong E., and Guay J. Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays. Can J Phys Pharmacol 75 (1997) 1088-1095